New drug combo shows promise for Hard-to-Treat stomach cancer

NCT ID NCT06504732

Recruiting now Disease control Sponsor: SUNHO（China）BioPharmaceutical CO., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug called IAH0968, given alone or with chemotherapy (CAPEOX), in people with advanced HER2-positive stomach cancer or other solid tumors. The goal is to see if the combination is safe and helps slow cancer growth better than standard treatment. About 574 adults aged 18-75 who have not had prior systemic therapy may join.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer gastric cancer gastric neoplasm gastroesophageal junction adenocarcinoma neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOR STOMACH NEOPLASMS

Contacts and locations

Locations

Harbin Medical University Cancer Hospital
RECRUITING

Harbin, Heilongjiang, 150081, China
The First Hospital of China Medical University
RECRUITING

Shenyang, Liaoning, 637000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.